Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Will China biotech be a hard pill to swallow for US Big Pharma?
If pharmaceutical drug patents are an hourglass turned over on the day of approval – with the approaching loss of exclusivity known in the industry as the “patent cliff” – then Big Pharma is currently watching the final…
Google to loosen pharma ad rules for AdMob authorized buyers
Google will update its Pharmaceutical policy for AdMob Authorized Buyers in January 2026, allowing prescription drug and prescription drug service ads in select markets — without requiring Google certification — while tightening…
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 –…
This is how exposed European Big Pharma is to the U.S.
The U.S. is the biggest single market for most pharma and biotech firms. Among the 10 largest biopharmaceutical companies in the Stoxx 600 health index, five get a majority of their total sales from the U.S. AstraZeneca gets 42% of sales from the…
Trump Works Deals w/ Pharma Companies, Nike Stock Plunges, More
Bloomberg News Now • Browse all episodes Listen for the latest from Bloomberg News…
Reversing Alzheimer's: The Forgotten Causes And Cures Big Pharma Buried
•Due to Alzheimer's research focusing on a symptom of it (amyloid plaques), rather than its actual cause, Alzheimer's has remained “incurable” for decades. •Rather than being a single disease, Alzheimer's has multiple…
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug prices to cheaper ones abroad. Pfizer…
Debunking Pharma Stigma: How Industry Partnerships Benefit Clinical Oncology Pharmacists
In the early 2000s, the pharmaceutical industry was largely driven by sales metrics. A few bad apples with limited morals pushed the envelope on acceptable sales techniques, leading to legal action and widespread mistrust of the entire…
Trump says U.S. drug prices will drop under new deals with pharma companies - National
U.S. President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align U.S. costs with those…
Rotten Tomatoes' for FDA, Pharma; Cancer Trial Halted; Cooked Food Tops Fresh
The FDA and four drug companies, one with a link to oncology, received 2025 'Rotten Tomatoes' awards from Fierce Biotech for representing 'strategic missteps, chaotic management, or just rotten luck.' Astellas and Pfizer announced that neoadjuvant…
Royalty Pharma (NASDAQ:RPRX) EVP Sells $3,060,375.22 in Stock
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP George Lloyd sold 79,346 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $38.57, for a total value of $3,060,375.22. Following the…
Trump adds nine more Pharma companies to 'most favored nation' drug-pricing program
Another 9 drug business have actually gotten on board with President Trump's “A lot of Preferred Country” drug rates program, bringing the overall variety of business taking part to 14 of the 17-largest drug makers. The current…
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 30,654 Shares of Stock
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP George Lloyd sold 30,654 shares of the firm's stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $38.50, for a total value of $1,180,179.00. The…
AstraZeneca Stock: Mispriced Growth Following The Oncology Segment Success (NASDAQ:AZN)
AstraZeneca targets $80bn revenue by FY2030, driven by oncology leadership and robust pipeline execution. AZN demonstrates double-digit revenue and EBITDA growth, trading at a discount to high-growth peers despite comparable operating leverage. DCF…
Pawan Kalyan Calls For People-Centric, Future-Ready Development
Holding one-on-one meetings with nine party legislators, Pawan Kalyan stressed the need for elected representatives to remain constantly accessible to the public and give top priority to resolving grievances. Development works, he said, must be…
Receive a Daily briefing on Pharma Industry News
Get Started